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Introduction
No evidence-based classification criteria are so far available
the majority of autoinflammatory diseases
Objectives
To elaborate and validate a set of clinical criteria able to
correctly classify patients affected with the most common
periodic fevers.
Methods
All FMF, TRAPS, MKD and CAPS patients enrolled in the
Eurofever registry until March 2013 were evaluated. For
each disease gold standards were considered according to
the following criteria: i) clinical validation by centers and
disease-principal investigator, ii) confirmative molecular
analysis (2 mutations for MEFV with at least one mutation
in exon 10, 2 mutations of MVK gene, 1 mutation of
TNFRFS1A with exclusion of low-penetrance variants, 1
mutation of NLRP3 with exclusion of low-penetrance var-
iants), iii) PFAPA patients validated by disease-principal
investigator and confirmed by the centers on the basis of
the follow-up. Clinical criteria was formulated on the basis
of a univariate and multivariate analysis in a first group of
patients (training set) and validated in an independent set
of patients (validation set).
Results
A total of 1204 consecutive patients with periodic fevers
were enrolled in the registry. Among them 743 consecu-
tive gold standard patients (288 FMF, 73 MKD, 96
TRAPS, 87 CAPS, 199 PFAPA) were evaluated (440 in the
training set and 303 in the validation set).The multivariate
analysis identified the clinical variables (either as presence
or absence).
The classification score was than tested in an indepen-
dent set of patients (validation set) revealing a sensitivity of
93% and specificity of 89% for FMF; a sensitivity of 100%
and specificity of 74% for TRAPS; a sensitivity of 80% and
specificity of 90% for MKD and sensitivity of 97% and spe-
cificity of 92% for CAPS; sensitivity of 99% and specificity
of 96% for PFAPA. The performance in non-gold standard
patients (i.e. heterozygous patients in autosomal recessive
diseases or patients with low-penetrance mutations)
revealed a variable percentage of patients (70% FMF, 75%
TRAPS, 41% MKD and 94% CAPS) positive for the respec-
tive criteria.
Independently correlated to for each disease with their
specific weight. The cut off value of the classification score
was chosen on the ROC curve in order to guarantee the
highest sensitivity and specificity.
Conclusion
Evidence-based clinical criteria for the classification of
patients with inherited periodic fevers have been elabo-
rated. These clinical criteria could be used in association
with molecular analysis and other variables (i.e. metabolic




Published: 8 November 2013
doi:10.1186/1546-0096-11-S1-A266
Cite this article as: Federici et al.: OR13-004 – Evidence-based clinical
classification criteria for periodic fevers. Pediatric Rheumatology 2013
11(Suppl 1):A266.
GASLINI, Genova, Italy
Federici et al. Pediatric Rheumatology 2013, 11(Suppl 1):A266
http://www.ped-rheum.com/content/11/S1/A266
© 2013 Federici et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
